Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
Author: Christina Wong
3 key ways AI-powered analysis supports drug development
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
5 guardrails you MUST implement when using AI in biopharma
Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology.
4 common use cases for an AI-powered drug pipeline analysis platform
Let’s explore the four most common use cases for an AI-powered drug pipeline analysis platform and how they support strategic decision-making in biopharma.
How can pharmaceutical companies improve pipeline analysis?
In biopharma, pipeline analysis provides comprehensive insights into the lifecycle of drug candidates, from discovery through clinical trials to market launch.
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.
4 major disruptions to the hunt for new cures, and how AI can help
The pursuit of novel cures in the pharmaceutical industry has always been a challenging endeavor. However, within the last decade or so, the landscape has become even more complex and disruptive due to several key factors. In this blog, we explore four major disruptions impacting the hunt for new cures and how artificial intelligence (AI)…
Revolutionizing Drug Development for Rare Diseases Through AI | Alok Tayi
“In this episode, Alok shares his personal story of how medical conditions in his family led to the creation of Vibe Bio, and how the company aims to identify diseases with unmet needs, leveraging AI to find medicines with the highest chances of providing cures.”
Mother-Son Duo Offer Biopharma KOL Mapping with Adnexi CEO Sandra Shpilberg
Sandra Shpilberg, Co-founder and CEO of Adnexi, discusses using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch.
Developing a Small Molecule for Duchenne Muscular Dystrophy with Frank Gleeson | VibeCast Episode 48
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, discusses groundbreaking small molecule therapies for Duchenne muscular dystrophy.